Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes i

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision

Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises

S&P 500 and Nasdaq 100 hit records as the 10-year yield retreats from a 24-year high; Constellat

Guardant Health reaches record highs as bullish patterns align across timeframes, opening potential

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced Cancer Rese

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

Privia Health Group (NASDAQ: PRVA - Get Free Report) and Guardant Health (NASDAQ: GH - Get Free Repo

Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the pr

Strong performance across the healthtech sector over the past two quarters has sparked renewed marke

CorVel (NASDAQ: CRVL - Get Free Report) and Guardant Health (NASDAQ: GH - Get Free Report) are both

Earning a spot on the IBD Leaderboard and IBD 50, Guardant Health stress tests a breakout.

Guardant Health (NASDAQ: GH - Get Free Report) and InfuSystem (NYSE: INFU - Get Free Report) are bot

Guardant Health, Inc. (NASDAQ: GH - Get Free Report) Director Alex Azar II sold 826 shares of Guarda

Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Trans

Second largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price tar

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co I

Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the fu

Largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

You found a great company, then watched it double before you got round to buying.

Bamco Inc. NY bought a new stake in Guardant Health, Inc. (NASDAQ: GH) during the undefined quarter,

Callan Family Office LLC bought a new stake in shares of Guardant Health, Inc. (NASDAQ: GH) in the s

Guardant Health must pay TwinStrand Biosciences and the University of Washington over $245 million a

Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight an

Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight

Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overw

Stifel analyst Daniel Arias maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price

RBC Capital analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Outperform and raise

Mizuho analyst Anthony Petrone maintains Guardant Health (NASDAQ:GH) with a Outperform and raises

JP Morgan analyst Casey Woodring maintains Guardant Health (NASDAQ:GH) with a Overweight and rais

TD Cowen analyst Dan Brennan maintains Guardant Health (NASDAQ:GH) with a Buy and raises the pric

U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other g

Analysts change outlook & price targets for Crocs, Monolithic Power, Axos Financial, Amazon, Kar

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price t

Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's

Guardant Health (NASDAQ:GH) raises FY2026 sales outlook from $1.300 billion-$1.320 billion to $1.340

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.42) per share which missed the analyst

Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the pr

Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and raises

Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overw

Citigroup analyst Patrick Donnelly maintains Guardant Health (NASDAQ:GH) with a Buy and raises th

Evercore ISI Group analyst Vijay Kumar maintains Guardant Health (NASDAQ:GH) with a Outperform an